Xavier Troussard Selected Research

Hairy Cell Leukemia

8/2022	Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy.
4/2022	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.
1/2022	A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia.
1/2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
7/2021	[Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?]
1/2021	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
6/2019	Variant form of hairy cell leukemia.
1/2018	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
9/2015	CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy.
1/2015	Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xavier Troussard Research Topics

Disease

12	Neoplasms (Cancer) 01/2020 - 10/2010
10	Hairy Cell Leukemia 08/2022 - 01/2015
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2022 - 08/2007
5	Splenomegaly 04/2022 - 12/2014
5	Multiple Myeloma 08/2011 - 12/2003
4	Leukocytosis (Pleocytosis) 01/2022 - 12/2014
4	Lymphoma (Lymphomas) 01/2018 - 07/2002
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2018 - 10/2006
3	Multiple Sclerosis 07/2014 - 05/2011
2	COVID-19 11/2022 - 01/2021
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2021 - 06/2015
2	Leukemia 10/2020 - 10/2017
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2017 - 10/2010
2	Infections 11/2016 - 07/2002
2	Lymphocytosis 03/2016 - 11/2010
1	B-Cell Lymphoma (Lymphoma, B Cell) 08/2022
1	Thrombocytopenia (Thrombopenia) 04/2022
1	Neutropenia 04/2022
1	Anemia 04/2022
1	Leukopenia 04/2022
1	Disease Progression 01/2022
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018
1	Prolymphocytic Leukemia 04/2017
1	Hemophilia A (Haemophilia) 11/2016
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2015
1	Second Primary Neoplasms (Neoplasms, Second) 08/2014
1	Persistent Polyclonal B-Cell Lymphocytosis 09/2011
1	Monoclonal Gammopathy of Undetermined Significance 10/2008
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 08/2003
1	Cytomegalovirus Infections (Inclusion Disease) 01/2003

Drug/Important Bio-Agent (IBA)

5	Biological ProductsIBA 04/2022 - 11/2010
4	Cyclin D1IBA 03/2011 - 12/2003
3	Messenger RNA (mRNA)IBA 11/2022 - 10/2006
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022 - 12/2017
3	Cladribine FDA LinkGeneric 01/2022 - 08/2014
3	Rituximab (Mabthera)FDA Link 01/2018 - 01/2015
3	Immunoglobulin M (IgM)IBA 03/2016 - 10/2008
3	Natalizumab (Tysabri)FDA Link 07/2014 - 05/2011
3	Proteins (Proteins, Gene)FDA Link 03/2011 - 08/2003
2	immunotoxin HA22IBA 01/2021 - 01/2018
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021 - 11/2016
2	InterferonsIBA 06/2015 - 07/2002
2	Pentostatin (Nipent)FDA LinkGeneric 01/2015 - 08/2014
2	Purine NucleosidesIBA 12/2014 - 08/2014
2	Antiviral Agents (Antivirals)IBA 01/2005 - 07/2002
1	VaccinesIBA 11/2022
1	2019-nCoV Vaccine mRNA-1273IBA 11/2022
1	BNT162 VaccineIBA 11/2022
1	A 17 (A-17)IBA 08/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022
1	ibrutinibIBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 10/2021
1	Immunotoxins (Immunotoxin)IBA 01/2018
1	Indicators and Reagents (Reagents)IBA 01/2018
1	Estrogen ReceptorsIBA 01/2018
1	Blood Proteins (Serum Proteins)IBA 10/2017
1	AnthracyclinesIBA 01/2017
1	Biological FactorsIBA 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2016
1	Factor VIII (Coagulation Factor VIII)IBA 11/2016
1	fludarabineIBA 02/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2016
1	bcr-abl Fusion ProteinsIBA 06/2015
1	purineIBA 01/2015
1	Immunoglobulins (Immunoglobulin)IBA 12/2014
1	Cyclin-Dependent Kinase Inhibitor p27IBA 09/2014
1	Edetic Acid (EDTA)FDA Link 09/2011
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2011
1	Thymidine KinaseIBA 11/2010
1	Benzene (Benzole)IBA 10/2010
1	SolventsIBA 10/2010
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 08/2007
1	RNA IsoformsIBA 10/2006
1	CyclinsIBA 10/2006
1	Valacyclovir (Valtrex)FDA LinkGeneric 01/2003
1	RNA (Ribonucleic Acid)IBA 07/2002
1	Ribavirin (Virazole)FDA LinkGeneric 07/2002
1	Interferon alpha-2 (Roferon-A)FDA Link 07/2002
1	Interferon-alpha (Interferon Alfa)IBA 07/2002

Therapy/Procedure

6	Therapeutics 08/2022 - 01/2015
3	Drug Therapy (Chemotherapy) 01/2018 - 09/2015
2	Stem Cell Transplantation 01/2018 - 09/2015
1	Precision Medicine 07/2021
1	Splenectomy 06/2019
1	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2018
1	Immunotherapy 01/2018
1	Salvage Therapy 12/2012
1	Kidney Transplantation 01/2003
1	Aftercare (After-Treatment) 07/2002